Cargando…

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

Ipilimumab, a monoclonal anti-CTLA4 antibody, paved the path for promising treatments, particularly in advanced forms of numerous cancers like melanoma. By blockading CTLA-4, ipilimumab can abolish the higher binding affinity of B7 for CTLA-4, setting CD28 free to act unlimited. This blockade can re...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimi, Amirali, Alilou, Sanam, Mirzaei, Hamid Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985548/
https://www.ncbi.nlm.nih.gov/pubmed/33767992
http://dx.doi.org/10.3389/fonc.2021.624780
_version_ 1783668271131656192
author Karimi, Amirali
Alilou, Sanam
Mirzaei, Hamid Reza
author_facet Karimi, Amirali
Alilou, Sanam
Mirzaei, Hamid Reza
author_sort Karimi, Amirali
collection PubMed
description Ipilimumab, a monoclonal anti-CTLA4 antibody, paved the path for promising treatments, particularly in advanced forms of numerous cancers like melanoma. By blockading CTLA-4, ipilimumab can abolish the higher binding affinity of B7 for CTLA-4, setting CD28 free to act unlimited. This blockade can result in an amplified antitumor immune response, and thereby, boosting more effective tumor regression. However, this blockage can lead to diminished self-tolerance and yielding autoimmune complications. The current review aims to describe adverse events (AEs) following the administration of ipilimumab in different cancers as every benefit comes at a cost. We will also discuss AEs in two different categories, melanoma and non-melanoma, owing to the possible shining promises in treating non-melanoma cancers. As the melanoma settings are more studied than other cancers, it might even help predict the patterns related to the other types of cancers. This similarity also might help physicians to predict adverse events and correctly manage them in non-melanoma cancers using the extensive findings reported in the more-studied melanoma settings. Recognizing the adverse events is vital since most of the adverse events could be reverted while carefully implementing guidelines. Finally, we will also describe the observed effectiveness of ipilimumab in non-melanoma cancers. This effectiveness reveals the importance of understanding the profile of adverse events in this group, even though some have not received FDA approval yet. Further clinical trials and careful systematic reviews may be required to decipher the hidden aspects of therapies with ipilimumab and its related AEs.
format Online
Article
Text
id pubmed-7985548
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79855482021-03-24 Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab Karimi, Amirali Alilou, Sanam Mirzaei, Hamid Reza Front Oncol Oncology Ipilimumab, a monoclonal anti-CTLA4 antibody, paved the path for promising treatments, particularly in advanced forms of numerous cancers like melanoma. By blockading CTLA-4, ipilimumab can abolish the higher binding affinity of B7 for CTLA-4, setting CD28 free to act unlimited. This blockade can result in an amplified antitumor immune response, and thereby, boosting more effective tumor regression. However, this blockage can lead to diminished self-tolerance and yielding autoimmune complications. The current review aims to describe adverse events (AEs) following the administration of ipilimumab in different cancers as every benefit comes at a cost. We will also discuss AEs in two different categories, melanoma and non-melanoma, owing to the possible shining promises in treating non-melanoma cancers. As the melanoma settings are more studied than other cancers, it might even help predict the patterns related to the other types of cancers. This similarity also might help physicians to predict adverse events and correctly manage them in non-melanoma cancers using the extensive findings reported in the more-studied melanoma settings. Recognizing the adverse events is vital since most of the adverse events could be reverted while carefully implementing guidelines. Finally, we will also describe the observed effectiveness of ipilimumab in non-melanoma cancers. This effectiveness reveals the importance of understanding the profile of adverse events in this group, even though some have not received FDA approval yet. Further clinical trials and careful systematic reviews may be required to decipher the hidden aspects of therapies with ipilimumab and its related AEs. Frontiers Media S.A. 2021-03-09 /pmc/articles/PMC7985548/ /pubmed/33767992 http://dx.doi.org/10.3389/fonc.2021.624780 Text en Copyright © 2021 Karimi, Alilou and Mirzaei http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Karimi, Amirali
Alilou, Sanam
Mirzaei, Hamid Reza
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
title Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
title_full Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
title_fullStr Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
title_full_unstemmed Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
title_short Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
title_sort adverse events following administration of anti-ctla4 antibody ipilimumab
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985548/
https://www.ncbi.nlm.nih.gov/pubmed/33767992
http://dx.doi.org/10.3389/fonc.2021.624780
work_keys_str_mv AT karimiamirali adverseeventsfollowingadministrationofantictla4antibodyipilimumab
AT alilousanam adverseeventsfollowingadministrationofantictla4antibodyipilimumab
AT mirzaeihamidreza adverseeventsfollowingadministrationofantictla4antibodyipilimumab